Creative Commons Open Access Journal No author-side fee 
  • Users Online: 119
  • Print this page
  • Email this page
Submit article
 
OPINION
Ahead of Print

Ischemic preconditioning for the treatment of COVID-19: Not only protection from cardiac ischemia


 Geriatric Rehabilitative Department, Rehabilitative Cardiology Unit, Italian National Research Center on Aging (IRCCS-INRCA), Contrada Mossa 2, 63900 Fermo, Italy

Correspondence Address:
Elpidio Santillo,
Geriatric Rehabilitative Department, Rehabilitative Cardiology Unit, Italian National Research Center on Aging (IRCCS-INRCA), Contrada Mossa 2, 63900 Fermo
Italy
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Ischemic preconditioning (IPC) is an innate mechanism of tissue protection from ischemia, which is easily replicable in clinical settings in the form of remote IPC. The final protective effect of IPC comprises the induction of favorable anti-inflammatory and anti-thrombotic molecular pathways. Recent studies on humans have confirmed that IPC protocols may exert cardioprotective actions. Moreover, IPC was also found to be capable of reducing surgical lung injury through the contrast of inflammatory response. Hence, IPC seems an ideal candidate to be tested as an innovative therapeutic weapon against a disease as coronavirus disease 19 (COVID-19), in which inflammation plays a key role. Interestingly, the use of IPC protocols for COVID-19 patients, beyond the potentiality of reducing the cardiologic complications, could also prove useful for the attenuation of inflammatory phenomena that characterize the course of coronavirus disease.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Santillo E
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed475    
    PDF Downloaded30    

Recommend this journal